SCHEMBL19181546

SCHEMBL19181546

C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CC[C@H](O)C(C)(C)[C@@H]1CC3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CRYAB P02511 6/20 1.00
CRYAA P02489 1/20 1.00
USP2 O75604 2/20 0.71
ALDH1A1 P00352 2/20 0.71
CYP3A4 P08684 2/20 0.71
MAPT P10636 2/20 0.71
ALOX15 P16050 2/20 0.71
LMNA P02545 1/20 0.71
PTGES O14684 2/20 0.58
FNTA P49354 1/20 0.54
FNTB P49356 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19181547 1.00 CRYAB (1.00) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL19194245 1.00 CRYAB (1.00) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL19194136 0.93 CRYAB (0.87) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL19198474 0.89 CRYAB (0.80) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL568417 0.89 CRYAB (0.80) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL7527661 0.89 CRYAB (0.80) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL288307 0.89 CRYAB (0.80) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL6130528 0.89 CRYAB (0.80) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL288306 0.89 CRYAB (0.80) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL13499192 0.89 CRYAB (0.80) CRYABCRYAAUSP2ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154193-A1 STEROID COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Cholesgen (Shanghai) Co., Ltd. (CN) 2025-05-15 US disclosed
WO-2024077793-A1 COMPOUND BASED ON OXIDATIVE STRESS AND ANTI-AMYLOID AGGREGATION MECHANISM, PREPARATION METHOD THEREFOR, AND USE THEREOF 浙江瑞瞳生物科技有限公司 2024-04-18 WO disclosed
CN-108884126-B Compounds for treating eye disorders or diseases 广州康睿生物医药科技股份有限公司 2022-03-18 CN disclosed
US-10093694-B2 Compounds for treating eye disorders or diseases GUANGZHOU KANGRUI BIOLOGICAL PHARMACEUTICAL TECHNOLOGY CO, LTD. (CN) 2018-10-09 US disclosed
WO-2017136549-A1 COMPOUNDS FOR TREATING EYE DISORDERS OR DISEASES YOUHEALTH BIOTECH, LIMITED (KY) 2017-08-10 WO disclosed
US-20170218009-A1 COMPOUNDS FOR TREATING EYE DISORDERS OR DISEASES GUANGZHOU KANGRUI BIOLOGICAL PHARMACEUTICAL TECHNOLOGIES CO., LTD. (CN) 2017-08-03 US disclosed
US-20170218009-A1 COMPOUNDS FOR TREATING EYE DISORDERS OR DISEASES GUANGZHOU KANGRUI BIOLOGICAL PHARMACEUTICAL TECHNOLOGIES CO., LTD. (CN) 2017-08-03 US disclosed
US-20170218009-A1 COMPOUNDS FOR TREATING EYE DISORDERS OR DISEASES GUANGZHOU KANGRUI BIOLOGICAL PHARMACEUTICAL TECHNOLOGIES CO., LTD. (CN) 2017-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10093694-B2 Compounds for treating eye disorders or diseases UACA, CRYAA, CLN6 CRYAB 4/4885CRYAA 2/4885USP2 915/4885
US-20170218009-A1 COMPOUNDS FOR TREATING EYE DISORDERS OR DISEASES UACA, CRYAA, CLN6 CRYAB 4/4885CRYAA 2/4885USP2 915/4885
US-20250154193-A1 STEROID COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SREBF1, SREBF2, CYP46A1 CRYAB 3795/4885CRYAA 4659/4885USP2 3504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.